UNITED STATES

1 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, 20549 FORM 10-Q QUARTERLY report PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 3, 2021OR TRANSITION report PURSUANT TO SECTION 13OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____COMMISSION FILE NUMBER 1-3619----PFIZER INC.(Exact name of registrant as specified in its charter)Delaware13-5315170(State of Incorporation)( Employer Identification No.)235 East 42 Street, New York, New York 10017(Address of principal executive offices) (zip code)(212) 733-2323(Registrant s telephone number)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, $.

2 05 par valuePFENew York Stock Notes due 2022 PFE22 New York Stock Notes due 2027 PFE27 New York Stock ExchangeIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for thepast 90 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of RegulationS-T ( of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

3 YesxNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2of the Exchange Act:Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

4 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes NoxAt November 8, 2021, 5,612,866,598 shares of the issuer s voting common stock were OF CONTENTSPART I. FINANCIAL INFORMATIONPageItem 1. Financial Statements Condensed Consolidated Statements of Income5 Condensed Consolidated Statements of Comprehensive Income6 Condensed Consolidated Balance Sheets7 Condensed Consolidated Statements of Equity8 Condensed Consolidated Statements of Cash Flows10 Notes to Condensed Consolidated Financial Statements11 Item s Discussion and Analysis of Financial Condition and Results of Operations39 Item 3.

5 Quantitative and Qualitative Disclosures About Market Risk62 Item 4. Controls and Procedures62 PART II. OTHER INFORMATION Item 1. Legal Proceedings62 Item 1A. Risk Factors62 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds62 Item 3. Defaults Upon Senior SecuritiesN/AItem 4. Mine Safety DisclosuresN/AItem 5. Other InformationN/AItem 6. Exhibits63 Signature63N/A = Not Applicable2 DEFINED TERMSU nless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc.

6 And itssubsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the is as of and for the three and nine months ended August 29, 2021 and August 23,2020, and for subsidiaries is as of and for the three and nine months ended October 3, 2021 and September 27, 2020. References to Notes in this Form 10-Qare to the notes to the condensed or consolidated financial statements in this Form 10-Q or our 2020 Form 10-K. We also have used several other terms in thisForm 10-Q, most of which are explained or defined:2020 Form 10-KAnnual report on Form 10-K for the fiscal year ended December 31, 2020 ACIPA dvisory Committee on Immunization PracticesALKanaplastic lymphoma kinaseAlliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or usAllogeneAllogene Therapeutics, BioPharma , Pharma Inc.

7 , Astellas US LLC and Astellas Pharma US, amyloid cardiomyopathyBioNTechBioNTech SEBLAB iologics License ApplicationBMSB ristol-Myers Squibb CompanyBNT162b2 Pfizer BioNTech COVID-19 VaccineComirnatyPfizer-BioNTech COVID-19 VaccineBODB oard of Centers for Disease Control and PreventionCMAconditional marketing authorizationConsumer Healthcare JVGSK Consumer Healthcare JVCOVID-19novel coronavirus disease of 2019 Developed EuropeIncludes the following markets: Western Europe, Scandinavian countries and FinlandDeveloped MarketsIncludes the following markets: , Developed Europe, Japan, Canada, South Korea, Australia and New ZealandDeveloped Rest of WorldIncludes the following markets: Japan, Canada, South Korea, Australia and New ZealandEMAE uropean Medicines AgencyEmerging MarketsIncludes, but is not limited to, the following markets.

8 Asia (excluding Japan and South Korea), Latin America, Central Europe,Eastern Europe, the Middle East, Africa and TurkeyEPSearnings per shareEUEuropean UnionEUAemergency use authorizationExchange ActSecurities Exchange Act of 1934, as Food and Drug AdministrationForm 10-QQuarterly report on Form 10-Q for the quarterly period ended October 3, 2021 GAAPG enerally Accepted Accounting PrinciplesGIST gastrointestinal stromal tumorsGSKG laxoSmithKline plcHospiraHospira, research and Internal Revenue ServiceJVjoint ventureKingKing Pharmaceuticals LLC (formerly King Pharmaceuticals.)

9 Inc.)LIBORL ondon Interbank Offered RateLillyEli Lilly & CompanyLOEloss of exclusivityMCOmanaged care organizationmCRCmetastatic colorectal cancermCRPC metastatic castration-resistant prostate cancermCSPC metastatic castration-sensitive prostate cancerMD&AManagement s Discussion and Analysis of Financial Condition and Results of OperationsMeridianMeridian Medical Technologies, collaborationa pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan that terminated on December 21,2020 MyovantMyovant Sciences castration-resistant prostate cancerNSCLCnon-small cell lung cancerOPKOOPKO Health, (SARS-CoV-2 3CL protease inhibitor (oral anti-viral)); ritonavirPBMpharmacy benefit managerPDUFAP rescription Drug User Fee ActPGSP fizer Global SupplyPharmaciaPharmacia CorporationPsApsoriatic arthritisQTDQ uarter-to-date or three months endedRArheumatoid arthritisRCCrenal cell carcinomaR&Dresearch and developmentSandozSandoz, Inc.

10 , a division of Novartis Securities and Exchange CommissionSI&Aselling, informational and administrativeUCulcerative StatesUpjohn BusinessPfizer s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globallyrecognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a genericsplatform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create ViatrisValnevaValneva SEViatrisViatris or nine months endedThis Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates.